DK1814846T3 - 11beta-HSD1-inhibitorer - Google Patents
11beta-HSD1-inhibitorerInfo
- Publication number
- DK1814846T3 DK1814846T3 DK05806462T DK05806462T DK1814846T3 DK 1814846 T3 DK1814846 T3 DK 1814846T3 DK 05806462 T DK05806462 T DK 05806462T DK 05806462 T DK05806462 T DK 05806462T DK 1814846 T3 DK1814846 T3 DK 1814846T3
- Authority
- DK
- Denmark
- Prior art keywords
- 11beta
- hsd1 inhibitors
- compounds
- relates
- hsd1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04026441A EP1655283A1 (en) | 2004-11-08 | 2004-11-08 | 11beta-HSD1 Inhibitors |
| PCT/EP2005/011933 WO2006048330A1 (en) | 2004-11-08 | 2005-11-08 | 11βετα-hsd1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1814846T3 true DK1814846T3 (da) | 2009-06-22 |
Family
ID=34927280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05806462T DK1814846T3 (da) | 2004-11-08 | 2005-11-08 | 11beta-HSD1-inhibitorer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090069323A1 (da) |
| EP (2) | EP1655283A1 (da) |
| JP (1) | JP2008518999A (da) |
| AT (1) | ATE427932T1 (da) |
| DE (1) | DE602005013812D1 (da) |
| DK (1) | DK1814846T3 (da) |
| WO (1) | WO2006048330A1 (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| BRPI0606256A2 (pt) | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| JP5133702B2 (ja) | 2005-01-05 | 2013-01-30 | アボット・ラボラトリーズ | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬 |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579504B2 (en) | 2005-12-07 | 2009-08-25 | Gilead Sciences, Inc. | ABCA1 elevating compounds |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| WO2007138112A2 (en) * | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| US9422235B2 (en) | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2744383C (en) | 2008-11-21 | 2017-04-25 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
| CN101838227A (zh) * | 2010-04-30 | 2010-09-22 | 孙德群 | 一种苯甲酰胺类除草剂的安全剂 |
| WO2012015715A1 (en) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
| KR20140027907A (ko) * | 2010-10-11 | 2014-03-07 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 치환된 벤즈아미드 및 그의 용도 |
| EP3363437B8 (en) | 2011-02-18 | 2021-11-03 | Endo Pharmaceuticals Inc. | Aminoindane compounds and use thereof in treating pain |
| EP2714681B1 (en) | 2011-05-25 | 2015-06-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| TW201343629A (zh) | 2012-01-31 | 2013-11-01 | Lilly Co Eli | 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物 |
| EA024182B1 (ru) | 2012-01-31 | 2016-08-31 | Эли Лилли Энд Компани | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| WO2014074365A1 (en) | 2012-11-06 | 2014-05-15 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
| TN2017000503A1 (en) | 2015-06-03 | 2019-04-12 | Bristol Myers Squibb Co | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| PL3571193T3 (pl) | 2017-01-23 | 2022-04-25 | Cadent Therapeutics, Inc. | Modulatory kanału potasowego |
| EP3684767A1 (en) | 2017-09-22 | 2020-07-29 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| DK3697785T3 (da) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine forbindelser som pad-inhibitorer |
| SG11202004143XA (en) | 2017-11-06 | 2020-06-29 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| US20060058315A1 (en) * | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
-
2004
- 2004-11-08 EP EP04026441A patent/EP1655283A1/en not_active Withdrawn
-
2005
- 2005-11-08 EP EP05806462A patent/EP1814846B1/en not_active Not-in-force
- 2005-11-08 US US11/667,114 patent/US20090069323A1/en not_active Abandoned
- 2005-11-08 DK DK05806462T patent/DK1814846T3/da active
- 2005-11-08 JP JP2007539549A patent/JP2008518999A/ja not_active Abandoned
- 2005-11-08 WO PCT/EP2005/011933 patent/WO2006048330A1/en active Application Filing
- 2005-11-08 AT AT05806462T patent/ATE427932T1/de not_active IP Right Cessation
- 2005-11-08 DE DE602005013812T patent/DE602005013812D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE427932T1 (de) | 2009-04-15 |
| EP1814846B1 (en) | 2009-04-08 |
| WO2006048330A8 (en) | 2006-10-05 |
| JP2008518999A (ja) | 2008-06-05 |
| EP1814846A1 (en) | 2007-08-08 |
| EP1655283A1 (en) | 2006-05-10 |
| US20090069323A1 (en) | 2009-03-12 |
| WO2006048330A1 (en) | 2006-05-11 |
| DE602005013812D1 (de) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE427932T1 (de) | 11beta-hsd1-inhibitoren | |
| NO20062644L (no) | DPP-IV inhibitorer | |
| NO20070089L (no) | DPP-IV inhibitorer | |
| NO20064032L (no) | DPP-IV inhibitorer | |
| ATE396190T1 (de) | Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase | |
| DE60330407D1 (de) | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung | |
| ATE490253T1 (de) | Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| MX2007004637A (es) | Sintesis asimetrica de derivados de dihidrobenzofurano. | |
| ATE441630T1 (de) | Substituierte cyclopenten-verbindungen | |
| WO2007047646A3 (en) | Substituted dihydro-isoindolones useful in treating kinase disorders | |
| SE0401762D0 (sv) | Novel compounds | |
| BR0306922A (pt) | N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina | |
| EA200602281A1 (ru) | Гетероарилсульфоны и сульфонамиды и их терапевтические применения | |
| ATE291024T1 (de) | Neue 4-aminofuropyrimidine und ihre verwendung | |
| BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
| JO2478B1 (en) | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists | |
| CY1107101T1 (el) | Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ | |
| EA200700179A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
| CO5690542A2 (es) | Metodo para la produccion de derivados de acil-fenil-urea sustituidos por animo-carbonilo y el uso de los mismos | |
| NO20053997L (no) | Oligosaccharidderivat | |
| CY1107097T1 (el) | 5ht4-ανταγωνιστικα βενζαμιδια 4-( αμινομεθυλ) - πιπεριδινης | |
| SE0403117D0 (sv) | New compounds 1 | |
| DE60213541D1 (de) | Discodermolid-Analoga und ihre pharmazeutische Verwendung |